Entity

Time filter

Source Type


Xu H.-G.,Suzhou Xiangcheng Peoples Hospital
Chinese Journal of Tissue Engineering Research | Year: 2014

BACKGROUND: For younger patients with intertrochanteric fractures, many fixation methods can provide an effective and robust fixation, but for elderly patients with osteoporosis intertrochanteric fracture, there remains debate for which fixation method is optimum. OBJECTIVE: To compare the clinical outcomes of proximal femoral nail anti-rotation and dynamic hip screw in the repair of intertrochanteric fracture. METHODS: Clinical data of patients with intertrochanteric fracture treated by proximal femoral nail anti-rotation or dynamic hip screw at the Suzhou Xiangcheng People’s Hospital from January 2010 to January 2013 were selected. In accordance with the inclusion criteria, 140 patients (146 hips) were included, containing 70 patients in the proximal femoral nail anti-rotation group (74 hips) and 70 patients in the dynamic hip screw group (72 hips). No significant difference in preoperative general data was detected in patients of both groups (P > 0.05), showing a comparability. Operative time, intra-operative blood loss, the average length of hospital stay, postoperative ambulation time, perioperative hemoglobin loss amount, postoperative complications, healing time, and Harris score were compared and evaluated in both groups. RESULTS AND CONCLUSION: 140 patients were followed up for 8-16 months. The incision was stage I healing. Compared with dynamic hip screw group, operative time, intra-operative blood loss, the average length of hospital stay, and postoperative ambulation time were better in the proximal femoral nail anti-rotation group (P < 0.05). However, no significant differences in perioperative hemoglobin loss amount, healing time, and postoperative Harris score were visible in the both groups (P > 0.05). These findings suggested that proximal femoral nail anti-rotation and dynamic hip screw in the repair of intertrochanteric fracture could obtain satisfactory clinical outcomes, but proximal femoral nail anti-rotation has some advantages such as short operative time, less blood loss, short mean hospital stay, early postoperative ambulation time and less postoperative complications. © 2014 Journal of Clinical Rehabilitative Tissue Engineering Research. All rights reserved. Source


Wang Y.,Nanjing Medical University | Wang Y.,Fudan University | Li D.,Fudan University | Xu N.,Nanjing Medical University | And 7 more authors.
Arthritis Research and Therapy | Year: 2011

Introduction: Follistatin-like protein 1 (FSTL1) is a secreted glycoprotein that has been implicated in arthritis pathogenesis in a mouse model. The aim of this study is to detect FSTL1 expression and to further assess its potential utility as a biomarker of joint damage in osteoarthritis (OA) patients.Methods: FSTL1 expression was detected by real-time PCR, western blot and immunohistochemistry (IHC) in the synovial tissues (STs) and by IHC in the articular cartilage from OA patients and control trauma patients. The serum and synovial fluid (SF) FSTL1 concentrations were measured by ELISA in OA patients and control individuals. Linear regression analyses were used to assess correlations between the serum FSTL1 levels and the clinical characteristics in OA patients.Results: The FSTL1 mRNA and protein levels were substantially elevated in the STs from OA patients compared with those from control trauma patients. The FSTL1 expression was strong in the cytoplasm of the synovial and capillary endothelial cells of the STs, but weak in the chondrocytes of the articular cartilage from OA patients. Furthermore, the serum and SF FSTL1 concentrations were significantly higher in OA patients than in respective control subjects. Interestingly, the serum and SF FSTL1 levels were markedly higher in female OA patients than in males. Importantly, bivariate regression analysis revealed that the serum FSTL1 levels in female OA patients had significant correlations with Kellgren and Lawrence (KL) grade, joint space narrowing (JSN) and the Western Ontario McMaster and Universities Osteoarthritis (WOMAC) stiffness subscale, an inverse correlation with height, and marginal correlations with the total WOMAC score and the WOMAC function subscale. Multivariate regression analysis revealed that the serum FSTL1 levels correlated independently with KL grade in female OA patients. Bivariate analysis also revealed that the serum FSTL1 levels correlated significantly with age and disease duration, and they correlated marginally with high sensitivity C-reactive protein (hs-CRP) and KL grade in male OA patients.Conclusions: Increased FSTL1 expression may be a characteristic of OA patients. FSTL1 is a potential serum biomarker that may reflect the severity of joint damage, and further studies are required to evaluate its potential application for monitoring the course of the disease and the efficacy of therapies in OA patients. © 2011 Wang et al.; licensee BioMed Central Ltd. Source


Xu H.,Soochow University of China | Chen K.,Soochow University of China | Jia X.,University of Houston | Tian Y.,Suzhou Xiangcheng Peoples Hospital | And 8 more authors.
Oncologist | Year: 2015

Background. Diabetic patients with breast cancer receiving metformin and neo adjuvant chemotherapy have a higher pathologic complete response rate than do diabetic patients not receiving met for min, but findings on salvage treatment have been inconsistent. We performed a meta-analysis to assess the effect of adding met for min to standard therapy on the prognosis of breast cancer patients with diabetes. Methods. We searched Pub Med, Em base, Web of Science (Thomson Scientific), China Knowledge Resource Integrated Database, VIP journal integration platform, and Chinese BioMedical Literature Database from inception to January 10, 2015, without language restrictions, including references related to met for min, breast cancer, and prognosis. We performed the meta-analysis using a random-effects model, with hazard ratios (HRs) and 95% confidence intervals (95% CIs) as effect measures. Results. A total of 11 studies consisting of 5,464 breast cancer patients with diabetes were included, comprising2, 760 patients who had received met for min and 2,704 patients who had not. The meta-analysis showed that met for min was associated with better overall survival times (HR: 0.53; 95% CI: 0.39-0.71) and cancer-specific survival times (HR: 0.89; 95% CI: 0.79-1.00). Subgroup analysis revealed that met for min improved the overall survival by 65% after adjusting for hormone receptor expression (HR: 0.35; 95% CI: 0.15-0.84). Taking met for min after the diagnosis of breast cancer was still associated with prolonged overall survival. Conclusion. The use of metformin in standard cancer therapy might improve both overall and cancer-specific survivals of diabetic patients with breast cancer © AlphaMed Press 2015. Source


Lian L.,Suzhou Xiangcheng Peoples Hospital | Li W.,Soochow University of China | Zhang Y.-T.,Soochow University of China | Zhao Y.-M.,Jiangsu Institute of Hematology | Tao M.,Soochow University of China
Chinese Journal of Cancer Prevention and Treatment | Year: 2014

OBJECTIVE: To investigate the molecular mechanisms implicated in human breast cancer MCF-7 cells induced platelet aggregation. METHODS: Different concentrations of MCF-7 cells were used to induce platelet aggregation(TCIPA). The four inhibitors (aspirin, apyrase, 7E3, SZ-1) were used to intervene in TCIPA. Platelet aggregation was expressed as the maximal percentage of aggregation rate, which was detected by light aggregometry. The cell morphology during TCIPA was observed by phase-contrast microscopy. The fluorescence intensity of GPIIb/IIIa and GPIb on the surface of platelets and tumour cells during TCIPA was measured by flow cytometry. ELISA was used to detect the release of thromboxaneA2 during TCIPA. RESULTS: The maximum platelet aggregation rate gradually increased with increasing of concentration of MCF-7. The cell morphology of platelet aggregation was observed by phase-contrast microscopy. During TCIPA, the expression levels of GPIIb/IIIa and GPIb receptors on platelets were (853±124, 137±21), and higher than those of control group. The expression of GPIIb/IIIa and GPIb receptors on MCF-7 cells were (178±22, 344±53). At different time points during TCIPA, platelet aggregation rate had positive correlation with expression of GPIIb/IIIa and GPIb(r=0.968, P=0.001; r=0.998, P<0.001), the expression levels of GPIIb/IIIa had positive correlation with expression of GPIb(r=0.971, P<0.001). The release level of TXB2 measured during TCIPA had no significant change(t=-1.362, P=0.210). Aspirin did not significantly inhibit the platelet aggregation rate induced by MCF-7 (t=0.069, P=0.946). In contrast to aspirin, Apyrase, 7E3, SZ-1 inhibited MCF-7-induced platelet aggregation rate significantly(21.5±1.3)%, (30.4±1.8)%, (26.7±1.2%) vs (43.3±1.7)%(t=28.03, P<0.001; t=13.38, P<0.001 and t=21.88, P<0.001). Combined inhibitory effects of these compounds abolished TCIPA induced by MCF-7 cells significantly. At the presence of inhibitors, the number and size of platelet clumps induced by MCF-7 were significantly reduced. The expression levels of GP IIb/IIIa and GPIb receptors on platelets were 532±40 and 117±10, and lower than these of inhibited group 853±124 and 137±21. Inhibitors of receptor glycoproteins could significantly inhibit expression of receptor glycoproteins on the surface of platelet(t=1.882, P=0.048; t=5.501, P=0.001) but not on the surface of MCF-7 cells(t=0.243, P=0.814; t=1.214, P=0.259). Inhibitors of platelet activation had no effect on the release of TXB2 during TCIPA(F=1.45, P=0.241). CONCLUSION: ADP-, GPIIb/IIIa-, GPIb-IX-mediated pathways of platelet activation may involve in MCF-7 cell induced platelet aggregation. Source


Luo C.-L.,Suzhou Xiangcheng Peoples Hospital | Wang S.-F.,Soochow University of China | Ma C.-T.,Suzhou Xiangcheng Peoples Hospital
World Chinese Journal of Digestology | Year: 2014

AIM: To assess the efficacy of glargine in the management of hepatogenic diabetes.METHODS: Eighty-two patients with hepatogenic diabetes treated with glargine were included in the study. The insulin dose was adjusted according to fasting blood glucose (FBG) till discharge. FBG, 2 h postprandial blood glucose (2 h PBG) and glycosylated hemoglobin (HbAlc) were monitored for 24 wk. HbAlc and blood glucose levels were compared before and after treatment.RESULTS: The FBG, 2 h PBG and HbAlc were significantly decreased after treatment (FBG: 6.35 mmol/L ± 1.47 mmol/L vs 10.52 mmol/L ± 3.13 mmol/L, P < 0.05; 2 h PBG: 9.81 mmol/L ± 3.14 mmol/L vs 17.51 mmol/L ± 4.33 mmol/L, P < 0.05; HbA1c: 7.54% ± 1.31% vs 10.65% ± 1.43%, P < 0.05). There were no significant differences in the above parameters between 12 and 24 wk after treatment (FBG: 6.47 mmol/L ± 1.25 mmol/L vs 6.35 mmol/ L ± 1.47 mmol/L, P > 0.05; 2 h PBG: 8.91 mmol/L ± 2.76 mmol/L vs 9.81 mmol/L ± 3.14 mmol/L, P > 0.05; HbA1c: 7.28% ± 1.12% vs 7.54% ± 1.31%, P > 0.05). The incidence of hypoglycemia was low, which occurred only once.CONCLUSION: Glargine therapy is effective and safe for hepatogenic diabetes. © 2014 Baishideng Publishing Group Inc. All rights reserved. Source

Discover hidden collaborations